Last reviewed · How we verify
stem and progenitor cells
Stem and progenitor cells are used to repair or replace damaged tissues and cells.
Stem and progenitor cells are used to repair or replace damaged tissues and cells. Used for Treatment of heart failure, Treatment of stroke.
At a glance
| Generic name | stem and progenitor cells |
|---|---|
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
Stem and progenitor cells have the ability to differentiate into various cell types, allowing them to repair or replace damaged tissues and cells. This process can be used to treat a range of conditions, including those affecting the heart, brain, and other organs.
Approved indications
- Treatment of heart failure
- Treatment of stroke
Common side effects
- Infection
- Graft-versus-host disease
Key clinical trials
- Quality of Life in Patients Who Have Undergone Stem Cell Transplant
- USC-Exos in Corpus Spongiosum Reconstruction for Hypospadias (NA)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart Failure (NYHA Class III-IV) (PHASE3)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Phase 1 Study of VELGRAFT, a Living Cellular Construct, in the Management of Chronic Diabetic Foot Ulcers Which Have Attained Granulation Tissue (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- stem and progenitor cells CI brief — competitive landscape report
- stem and progenitor cells updates RSS · CI watch RSS
- Universitaire Ziekenhuizen KU Leuven portfolio CI